APA-viite (7. p.)

Jamadagni, S., Pandkar, P., Saundankar, T., Shirke, G., Malekar, S., & Vaidya, V. (2022). Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial. Elsevier.

Chicago-viite (17. p.)

Jamadagni, Sameer, Prasad Pandkar, Tushar Saundankar, Girish Shirke, Shailesh Malekar, ja V.G Vaidya. Efficacy of Madhav Rasayan Plus as Adjuvant in Moderate COVID-19 Patients: Preliminary Outcomes of Randomized Controlled Trial. Elsevier, 2022.

MLA-viite (9. p.)

Jamadagni, Sameer, et al. Efficacy of Madhav Rasayan Plus as Adjuvant in Moderate COVID-19 Patients: Preliminary Outcomes of Randomized Controlled Trial. Elsevier, 2022.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.